Sutro Biopharma (NASDAQ:STRO – Get Free Report) is one of 843 publicly-traded companies in the “Biotechnology” industry, but how does it contrast to its peers? We will compare Sutro Biopharma to similar businesses based on the strength of its valuation, dividends, risk, earnings, analyst recommendations, institutional ownership and profitability.
Institutional & Insider Ownership
97.0% of Sutro Biopharma shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 1.8% of Sutro Biopharma shares are held by company insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Risk and Volatility
Sutro Biopharma has a beta of 1.56, suggesting that its share price is 56% more volatile than the S&P 500. Comparatively, Sutro Biopharma’s peers have a beta of -1.84, suggesting that their average share price is 284% less volatile than the S&P 500.
Profitability
This table compares Sutro Biopharma and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sutro Biopharma | -344.22% | N/A | -76.33% |
| Sutro Biopharma Competitors | -12,224.09% | -202.33% | -31.23% |
Valuation & Earnings
This table compares Sutro Biopharma and its peers revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Sutro Biopharma | $102.48 million | -$191.09 million | -0.77 |
| Sutro Biopharma Competitors | $768.41 million | $11.71 million | -18.32 |
Sutro Biopharma’s peers have higher revenue and earnings than Sutro Biopharma. Sutro Biopharma is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Analyst Recommendations
This is a breakdown of current recommendations and price targets for Sutro Biopharma and its peers, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sutro Biopharma | 1 | 0 | 10 | 2 | 3.00 |
| Sutro Biopharma Competitors | 9923 | 15317 | 45692 | 1603 | 2.54 |
Sutro Biopharma presently has a consensus target price of $49.60, indicating a potential upside of 435.98%. As a group, “Biotechnology” companies have a potential upside of 131.31%. Given Sutro Biopharma’s stronger consensus rating and higher possible upside, research analysts clearly believe Sutro Biopharma is more favorable than its peers.
Summary
Sutro Biopharma beats its peers on 9 of the 13 factors compared.
About Sutro Biopharma
Sutro Biopharma is a biotechnology company focused on discovering and developing targeted cancer treatments. Its research has centered on antibody-drug conjugates (ADCs), which use antibodies to deliver cancer-fighting drugs to selected cells. The company developed its XpressCF+ platform, a cell-free protein synthesis and site-specific conjugation technology intended to support the design and production of biologic medicines. Sutro’s clinical-stage programs have included luveltamab tazevibulin, an ADC targeting folate receptor alpha, and STRO-003, an ADC targeting ROR1.
Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
